Académique Documents
Professionnel Documents
Culture Documents
Objetivo
Comparar antipsicticos de primera y segunda
generacin en trminos de efectividad y
tolerabilidad en el tiempo
Diseo
16 clnicas universitarias
7 Instituciones de veteranos
4 centros privados
Diseo
Participantes
1460 pacientes
Diseo
Criterios de inclusin/exclusin
Intervencin
Intervencin
RESULTADOS PRINCIPALES
DISCONTINUACION POR
CUALQUIER CAUSA (n 1432)
Cualquier causa
74.1%
Falta de eficacia
23.7%
Intolerancia
14.9%
Decisin del paciente
29.9%
Overall p-value=.004*
Olanzapine
Perphenazine
Quetiapine
Risperidone
Ziprasidone
0.8
0.6
0.4
0.2 p<.001 for olanzapine vs quetiapine
p=.002 for olanzapine vs risperidone
0
0
3
6
9
12
15
18
CATIE
1.0
0.8
Olanzapine
Perphenazine
Quetiapine
Risperidone
Ziprasidone
0.6
0.4
0.2
0
3
6
9
12
15
18
Time to Discontinuation for Lack of Efficacy (Months)
PANSS TOTAL
0
Olanzapine
Perphenazine
Quetiapine
Risperidone
Ziprasidone
-2
-4
-6
-8
-10 p=.001 for time-by-treatment interaction
-12 p=.065 for ziprasidone cohort
0
3
6
9
12
Months
15
18
Interaction of time treatment indicates significant variation in treatment effects over time.
Improvement was initially greatest with olanzapine but its advantage diminished over time.
The number of patients declines over assessment times. Least-square mean estimates are
from a mixed model, which assumes that data are missing at random. Values at later
timepoints are based on the observed data for continuing patients as well as estimated data
for discontinued patients.
PANSS NEGATIVO
0.5
Olanzapine
Perphenazine
Quetiapine
Risperidone
Ziprasidone
0
-0.5
-1
-1.5
-2
-2.5 p=.177 for time-by-treatment interaction
p=.019 for ziprasidone cohort
-3
0
3
6
9
12
Months
15
18
NECESIDAD DE HOSPITALIZACION
POR RECAIDA
100
p<.001
90
80
70
%
60
50
40
30
20
10
11%
16%
20%
15%
18%
RIS
ZIP
0
OLZ
PER
QUET
CONCLUSIONES CATIE I
Lieberman, APA, 06
Discusion
Discusion
Anlisis Crtco
SI
Si
si
si
Anlisis Crtco
SI
Si
si
Anlisis Crtco
SI
Si
3,-
si
si